

*Edited by  
János Fischer and  
C. Robin Ganellin*

**Analogue-based Drug  
Discovery II**

*Edited by*  
*János Fischer and C. Robin Ganellin*

## **Analogue-based Drug Discovery II**



WILEY-VCH Verlag GmbH & Co. KGaA

**MPI EXHIBIT 1033 PAGE 2**

**The Editors**

**Prof. Dr. János Fischer**

Richter Plc  
Gyömrői ut 30  
1103 Budapest  
Hungary

**Prof. Dr. C. Robin Canellin**

University College London  
Department of Chemistry  
20 Gordon Street  
London WC1H 0AJ  
United Kingdom

**Supported by**

The International Union of Pure and Applied  
Chemistry (IUPAC)  
Chemistry and Human Health Division  
PO Box 13757  
Research Triangle Park, NC 27709-3757  
USA

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.:** applied for

**British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

**Bibliographic information published by the Deutsche Nationalbibliothek**

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Cover Design** Adam Design, Weinheim

**Typesetting** Thomson Digital, Noida, India

**Printing and Binding** Strauss GmbH, Mörlenbach

Printed in the Federal Republic of Germany  
Printed on acid-free paper

**ISBN:** 978-3-527-32549-8

## Contents

<b>Preface</b>	XV
<b>Introduction</b>	XVII
<b>Abbreviations</b>	XXI

<b>Part I</b>	<b>General Aspects</b>	<b>1</b>
<b>1</b>	<b>Optimizing Drug Therapy by Analogues</b>	<b>3</b>
	<i>János Fischer, C. Robin Ganellin, John Proudfoot, and Erika M. Alapi</i>	
1.1	Introduction	3
1.2	Pharmacodynamic Characteristics	4
1.2.1	Potency	4
1.2.2	Improving the Ratio of Main Activity and Adverse Effects	5
1.2.2.1	Improving Selectivity Through Receptor Subtypes	6
1.2.2.2	Improving Selectivity Through Unrelated Receptors	7
1.2.2.3	Improving Selectivity by Tissue Distribution	7
1.2.2.4	Improving Selectivity of Nonreceptor-Mediated Effects	10
1.2.3	Improving the Physicochemical Properties with Analogues	10
1.2.4	Analogues to Reduce the Resistance to Anti-Infective Drugs	11
1.2.4.1	Antibiotics	11
1.2.4.2	Antifungal Drugs	12
1.2.4.3	Antiviral Drugs	12
1.2.5	Analogue Research in Resistance to Drug Therapies in Cancer Treatment	15
1.3	Pharmacokinetic Characteristics	15
1.3.1	Improving Oral Bioavailability	15
1.3.1.1	Improving Absorption	16
1.3.1.2	Improving Metabolic Stability	16
1.3.2	Drugs with a Long Duration of Action	17
1.3.3	Ultrashort-Acting Drugs	18
1.3.4	Decreasing Interindividual Pharmacokinetic Differences	20
1.3.5	Decreasing Systemic Activity	21

vi | Contents

1.4	Drug Interactions	22
1.4.1	Decreasing Drug Interactions	22
1.4.2	Increasing Drug Interactions	23
1.5	Summary	23
	References	24
<b>2</b>	<b>Standalone Drugs</b>	<b>29</b>
	<i>János Fischer, C. Robin Ganellin, Arun Ganesan, and John Proudfoot</i>	
2.1	Acetaminophen (Paracetamol)	30
2.2	Acetylsalicylic Acid (Aspirin)	33
2.3	Aripiprazole	35
2.3.1	First Generation “Typical” Antipsychotic Drugs (Other Names: Neuroleptics, Conventional Antipsychotics)	36
2.3.2	Second-Generation “Atypical” Antipsychotic Drugs	37
2.3.3	A New Approach: Aripiprazole, a Dopamine Partial Agonist	38
2.4	Bupropion	39
2.5	Ezetimibe	42
2.6	Lamotrigine	46
2.7	Metformin	47
2.8	Topiramate	49
2.9	Valproate	51
2.10	Summary	52
	References	53
<b>3</b>	<b>Application of Molecular Modeling in Analogue-Based Drug Discovery</b>	<b>61</b>
	<i>György C. Ferenczy</i>	
3.1	Introduction	61
3.2	Cilazapril: An ACE Inhibitor	62
3.3	Atorvastatin: A HMG-CoA Reductase Inhibitor	66
3.4	PDE4 Inhibitors	70
3.5	GPIIb/IIIa Antagonists	73
3.6	HIV Protease Inhibitors	74
3.7	Epilogue	79
	References	79
<b>4</b>	<b>Issues for the Patenting of Analogues</b>	<b>83</b>
	<i>Stephen C. Smith</i>	
4.1	Introduction	83
4.2	Patents: Some Fundamentals	84
4.3	Patentability	85
4.4	Important Elements of the International Patent System	86
4.5	Priority	87
4.6	Novelty	88
4.7	Inventive Step: Nonobviousness	90

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.